Skip to content

Prognostic Study of Via Dynamic Change of PCA3 mRNA in Drainage Fluid After Radical Prostatectomy

Prognostic Study of Prostate Cancer Via Dynamic Change of PCA3 mRNA in Abdominal Cavity Drainage Fluid After Radical Prostatectomy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06707961
Enrollment
100
Registered
2024-11-27
Start date
2024-12-01
Completion date
2025-12-01
Last updated
2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exosomes, Prostatic Neoplasms

Brief summary

This study investigates the prognostic value of dynamic changes in PCA3 mRNA levels found in the abdominal cavity drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PCA3 mRNA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.

Detailed description

This study examines the prognostic significance of PCA3 mRNA levels in the drainage fluid collected from the abdominal cavity following radical prostatectomy, a common surgical treatment for prostate cancer. PSA is widely used as a biomarker for prostate cancer diagnosis, treatment response, and recurrence monitoring in the blood. However, this research seeks to explore the prognostic value of PCA3 mRNA in the drainage fluid. The study involves continuous monitoring of PCA3 mRNA levels in the drainage fluid after radical prostatectomy, with the hypothesis that dynamic changes in these levels could serve as an early warning system for potential tumor recurrence, residual disease, or metastasis. The research will correlate these fluid PCA3 mRNA levels with patient outcomes, recurrence rates, and other clinical factors to determine their predictive value. By investigating this novel source of PCA3 mRNA monitoring, the study aims to reduce invasive tests, enhance post-operative surveillance, and improve early detection of disease recurrence for prostate cancer patients. This research could contribute to refining post-surgical care protocols, offering a new tool for predict long-term outcomes for individuals undergoing radical prostatectomy.

Interventions

None listed

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

•Prostate cancer patients treated with radical prostatectomy

Exclusion criteria

* 1\. Received neoadjuvant endocrine/chemotherapy before surgery; * 2\. Urine leakage after surgery (positive creatinine test of drainage fluid).

Design outcomes

Primary

MeasureTime frameDescription
PCA3 mRNA Levels in Drainage FluidMeasured daily for up to 3 days post-surgeryPCA3 mRNA Levels in The Drainage Fluid Drained from The Abdominal Cavity

Contacts

Primary ContactHuaqi Zhan
0HuaChang@sjtu.edu.cn18817532325

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026